The stock may react positively to the strengthened balance sheet and strategic focus on NXT-41x, but traders should monitor whether declining core revenue can be reversed with the new product launch. The release of $8.0 million in escrow in Q4 2026 provides a future cash milestone.
Price Chart
Executive Summary
Elutia reported its 2025 financial results, highlighted by the $88 million sale of its BioEnvelope business to Boston Scientific, which generated a net income of $53.4 million for the year. The company strengthened its balance sheet, repaid $26.9 million in debt, and now holds $44.4 million in cash and escrow. It also advanced its NXT-41x development program and initiated a strategic review of its SimpliDerm product line to focus on upcoming commercialization.
Key Financial Metrics
Key Facts
- Closed $88 million sale of BioEnvelope business to Boston Scientific in Q4 2025
- Full-year 2025 net income was $53.4 million (vs. $53.9 million net loss in 2024), driven by the gain on divestiture
- Full-year 2025 revenue from continuing operations declined 15.2% to $12.3 million (from $14.5 million)
- Company repaid $26.9 million in debt and ended 2025 with $36.4 million in cash and $8.0 million in escrow
- NXT-41 regulatory submission made; clearance expected in second half of 2026
- Initiated strategic process to explore options for SimpliDerm product line
Financial Impact
Revenue from continuing operations declined 15.2% YoY to $12.3 million in 2025, while net income turned positive at $53.4 million due to $88 million gain on divestiture
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| SimpliDerm | $9.1M | -21.6% |
| Cardiovascular | $3.2M | +10.3% |
Risk Factors
- Core revenue (continuing operations) declined significantly in 2025
- Future performance now heavily dependent on successful launch of NXT-41x
- Strategic review of SimpliDerm introduces uncertainty around that product line
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-026398 |
| Document: elut-20260303x8k.htm | 0001104659-26-026398 |
| Document: 0001104659-26-026398-index-headers.html | 0001104659-26-026398 |
| Document: 0001104659-26-026398-index.html | 0001104659-26-026398 |
| Document: 0001104659-26-026398.txt | 0001104659-26-026398 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 31, 2026 9w ago | Press Release | $0.8568 $0.8800 | ▲ +2.71% | ▼ −0.28% | $0.7787 (−9.12%) |
Jun 16, 2026 15w ago | 8-K | $0.9914 $0.9500 | ▼ −4.18% | ▼ −5.49% | $0.7787 (−21.45%) |
May 14, 2026 20w ago | 8-K | $1.03 $0.9690 | ▼ −5.92% | ▼ −8.04% | $0.7787 (−24.40%) |
Mar 11, 2026 29w ago | 8-K | $1.15 $1.13 | ▼ −1.74% | ▼ −3.71% | $0.7787 (−32.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access